SCPH SCPharmaceuticals Inc

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.

Events:

TD Cowen 44th Annual Health Care Conference

Wednesday, March 6, 2024

Fireside Chat: 12:50 p.m. EST

Leerink Partners Global Biopharma Conference

Tuesday, March 12, 2024

Presentation: 2:20 p.m. EST

A live webcast of both presentations can be accessed under “News & Events” in the Investor Relations section of the Company’s website, .

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit .

Katherine Miranda

scPharmaceuticals Inc., 781-301-6869

Investors:

PJ Kelleher

LifeSci Advisors, 617-430-7579



EN
28/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE

scPharmaceuticals to Announce First Quarter 2024 Financial Results on ...

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024 Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results ...

 PRESS RELEASE

scPharmaceuticals Announces First Participant Enrolled in Pivotal Phar...

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the deli...

 PRESS RELEASE

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Finan...

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January Ended 2023 with cash, cash equivalents and short-term investments of $76 million Company to host investor conference call and webcast today, Wednesday, March 13, at 4:30pm ET BURLINGTON...

 PRESS RELEASE

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financ...

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024 Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 13, 2024, to discuss...

 PRESS RELEASE

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

scPharmaceuticals to Participate in Two Upcoming Investor Conferences BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences. Events: TD Cowen 44th Annual Health Care ConferenceWednesday, March 6, 2024Fireside Chat: 12:50 p.m. EST L...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch